Literature DB >> 9230381

Genotypic analysis of Burkholderia cepacia isolates from 13 French cystic fibrosis centers.

C Segonds1, E Bingen, G Couetdic, S Mathy, N Brahimi, N Marty, P Plesiat, Y Michel-Briand, G Chabanon.   

Abstract

Burkholderia cepacia has been involved in outbreaks of pulmonary infection among patients with cystic fibrosis (CF), and the spread of a highly transmissible clone has been reported throughout the United Kingdom and Canada. These data prompted a DNA-based typing study of the strains recovered in French CF centers. Ninety-five isolates recovered from 71 patients attending 13 CF centers in 9 regions of France were characterized by randomly amplified polymorphic DNA (RAPD) analysis and pulsed-field gel electrophoresis (PFGE). Twenty-one genotypes were identified among the 95 isolates, and the results of RAPD and PFGE were concordant for 89 isolates (94%). Cross-colonization was demonstrated in 7 of the 13 CF centers. The investigation of serial isolates showed that most chronically colonized patients harbored a single B. cepacia strain. A geographically clustered distribution of B. cepacia genotypes was observed, except for one genotype, which was detected in four regions but was proven to be different from the genotype of the British-Canadian highly transmissible strain. The present study confirms the ability of B. cepacia to spread among CF communities in France and the importance of epidemiological surveys in the institution of prevention policies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9230381      PMCID: PMC229902          DOI: 10.1128/jcm.35.8.2055-2060.1997

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  39 in total

1.  Enterobacterial intergenic consensus sequence polymerase chain reaction as a typing method for Burkholderia (Pseudomonas) cepacia.

Authors:  Nevio Cimolai; Colleen Trombley
Journal:  Clin Microbiol Infect       Date:  1996-08       Impact factor: 8.067

2.  Burkholderia cepacia and cystic fibrosis: do natural environments present a potential hazard?

Authors:  S L Butler; C J Doherty; J E Hughes; J W Nelson; J R Govan
Journal:  J Clin Microbiol       Date:  1995-04       Impact factor: 5.948

3.  Recovery of Pseudomonas gladioli from respiratory tract specimens of patients with cystic fibrosis.

Authors:  J C Christenson; D F Welch; G Mukwaya; M J Muszynski; R E Weaver; D J Brenner
Journal:  J Clin Microbiol       Date:  1989-02       Impact factor: 5.948

Review 4.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

5.  Epidemiology of Burkholderia cepacia infection in patients with cystic fibrosis: analysis by randomly amplified polymorphic DNA fingerprinting.

Authors:  E Mahenthiralingam; M E Campbell; D A Henry; D P Speert
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

6.  The emergence of a highly transmissible lineage of cbl+ Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain.

Authors:  L Sun; R Z Jiang; S Steinbach; A Holmes; C Campanelli; J Forstner; U Sajjan; Y Tan; M Riley; R Goldstein
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

7.  Linkage analysis of geographic and clinical clusters in Pseudomonas cepacia infections by multilocus enzyme electrophoresis and ribotyping.

Authors:  W M Johnson; S D Tyler; K R Rozee
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

8.  Type characterisation and antibiotic susceptibility of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis in the United Kingdom and the Republic of Ireland.

Authors:  T L Pitt; M E Kaufmann; P S Patel; L C Benge; S Gaskin; D M Livermore
Journal:  J Med Microbiol       Date:  1996-03       Impact factor: 2.472

9.  Transmissibility of Pseudomonas cepacia infection in clinic patients and lung-transplant recipients with cystic fibrosis.

Authors:  S Steinbach; L Sun; R Z Jiang; P Flume; P Gilligan; T M Egan; R Goldstein
Journal:  N Engl J Med       Date:  1994-10-13       Impact factor: 91.245

10.  Characterization of PCR-ribotyping for Burkholderia (Pseudomonas) cepacia.

Authors:  S E Dasen; J J LiPuma; J R Kostman; T L Stull
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

View more
  12 in total

1.  Phenotypic methods for determining genomovar status of the Burkholderia cepacia complex.

Authors:  D A Henry; E Mahenthiralingam; P Vandamme; T Coenye; D P Speert
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

2.  C-terminal region of Pseudomonas aeruginosa outer membrane porin OprD modulates susceptibility to meropenem.

Authors:  S F Epp; T Köhler; P Plésiat; M Michéa-Hamzehpour; J Frey; J C Pechère
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Differentiation of Burkholderia species by PCR-restriction fragment length polymorphism analysis of the 16S rRNA gene and application to cystic fibrosis isolates.

Authors:  C Segonds; T Heulin; N Marty; G Chabanon
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

4.  Identification and population structure of Burkholderia stabilis sp. nov. (formerly Burkholderia cepacia genomovar IV).

Authors:  P Vandamme; E Mahenthiralingam; B Holmes; T Coenye; B Hoste; P De Vos; D Henry; D P Speert
Journal:  J Clin Microbiol       Date:  2000-03       Impact factor: 5.948

5.  Development of a multiple-locus variable-number tandem-repeat typing scheme for genetic fingerprinting of Burkholderia cenocepacia and application to nationwide epidemiological analysis.

Authors:  Christine Segonds; Michelle Thouverez; Antoine Barthe; Nadège Bossuet-Greif; Lenka Tisseyre; Patrick Plésiat; Gilles Vergnaud; Gérard Chabanon; Christine Pourcel
Journal:  J Clin Microbiol       Date:  2014-11-19       Impact factor: 5.948

6.  Comparative assessment of genotyping methods for epidemiologic study of Burkholderia cepacia genomovar III.

Authors:  Tom Coenye; Theodore Spilker; Alissa Martin; John J LiPuma
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

7.  Species distribution and ribotype diversity of Burkholderia cepacia complex isolates from French patients with cystic fibrosis.

Authors:  Sylvain Brisse; Christophe Cordevant; Peter Vandamme; Philippe Bidet; Chawki Loukil; Gérard Chabanon; Marc Lange; Edouard Bingen
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

8.  Elucidating global epidemiology of Burkholderia multivorans in cases of cystic fibrosis by multilocus sequence typing.

Authors:  Adam Baldwin; Eshwar Mahenthiralingam; Pavel Drevinek; Chris Pope; David J Waine; Deborah A Henry; David P Speert; Phil Carter; Peter Vandamme; John J LiPuma; Chris G Dowson
Journal:  J Clin Microbiol       Date:  2007-11-21       Impact factor: 5.948

9.  Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis.

Authors:  S Bonacorsi; F Fitoussi; S Lhopital; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

Review 10.  Agricultural use of Burkholderia (Pseudomonas) cepacia: a threat to human health?

Authors:  A Holmes; J Govan; R Goldstein
Journal:  Emerg Infect Dis       Date:  1998 Apr-Jun       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.